The launching and completion of many clinical trials targeting cancer cell metabolism in a variety of cancer types using small molecules that hit pivotal Myc-dependent metabolic enzymes and pathways, including astrocytomas and gliomas, highlights the importance of providing an in-depth characterization of this Myc-centered circuit in GBM as a way to design novel therapeutic strategies aimed at increasing the pool of weapons against this deadly type of tumor. The gene discussed is MYC; the disease is central nervous system cancer.